Overcoming Resistance of Melanoma to Immunotherapy with Monoclonal Antibodies Against Checkpoints Inhibitors View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

2013-08-04

AUTHORS

Peter Hersey , Stuart Gallagher , Branka Mijatov

ABSTRACT

The introduction of monoclonal antibodies against checkpoint inhibitors on T cells such as Ipilimumab and anti PD1 has been a major advance in the treatment of metastatic melanoma. Nevertheless, the majority of patients does not receive benefit from this treatment approach. The reasons for this are likely to reflect conditioning of the microenvironment of the tumour by properties of the tumour cells that either prevent infiltration by T cells or which modulate their function. Treatments that combine monoclonal antibodies with agents that inhibit melanoma cell production of suppressive cytokines and which favor infiltration of T cells into the tumour are the focus of ongoing studies. More... »

PAGES

143-155

Book

TITLE

Resistance to Immunotherapeutic Antibodies in Cancer

ISBN

978-1-4614-7653-5
978-1-4614-7654-2

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/978-1-4614-7654-2_7

DOI

http://dx.doi.org/10.1007/978-1-4614-7654-2_7

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1009856817


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Immunology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Kolling Institute of Medical Research, Royal North Shore Hospital, 2065, St Leonards, NSW, Australia", 
          "id": "http://www.grid.ac/institutes/grid.412703.3", 
          "name": [
            "Kolling Institute of Medical Research, Royal North Shore Hospital, 2065, St Leonards, NSW, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hersey", 
        "givenName": "Peter", 
        "id": "sg:person.01073667716.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01073667716.42"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Kolling Institute of Medical Research, Royal North Shore Hospital, 2065, St Leonards, NSW, Australia", 
          "id": "http://www.grid.ac/institutes/grid.412703.3", 
          "name": [
            "Kolling Institute of Medical Research, Royal North Shore Hospital, 2065, St Leonards, NSW, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gallagher", 
        "givenName": "Stuart", 
        "id": "sg:person.01167006216.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01167006216.55"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Kolling Institute of Medical Research, Royal North Shore Hospital, 2065, St Leonards, NSW, Australia", 
          "id": "http://www.grid.ac/institutes/grid.412703.3", 
          "name": [
            "Kolling Institute of Medical Research, Royal North Shore Hospital, 2065, St Leonards, NSW, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mijatov", 
        "givenName": "Branka", 
        "id": "sg:person.01140040522.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01140040522.17"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2013-08-04", 
    "datePublishedReg": "2013-08-04", 
    "description": "The introduction of monoclonal antibodies against checkpoint inhibitors on T cells such as Ipilimumab and anti PD1 has been a major advance in the treatment of metastatic melanoma. Nevertheless, the majority of patients does not receive benefit from this treatment approach. The reasons for this are likely to reflect conditioning of the microenvironment of the tumour by properties of the tumour cells that either prevent infiltration by T cells or which modulate their function. Treatments that combine monoclonal antibodies with agents that inhibit melanoma cell production of suppressive cytokines and which favor infiltration of T cells into the tumour are the focus of ongoing studies.", 
    "editor": [
      {
        "familyName": "Bonavida", 
        "givenName": "Benjamin", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-1-4614-7654-2_7", 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-1-4614-7653-5", 
        "978-1-4614-7654-2"
      ], 
      "name": "Resistance to Immunotherapeutic Antibodies in Cancer", 
      "type": "Book"
    }, 
    "keywords": [
      "T cells", 
      "checkpoint inhibitors", 
      "monoclonal antibodies", 
      "majority of patients", 
      "Anti-PD1", 
      "suppressive cytokines", 
      "metastatic melanoma", 
      "treatment approaches", 
      "tumor cells", 
      "overcoming resistance", 
      "antibodies", 
      "ongoing studies", 
      "melanoma", 
      "tumors", 
      "cell production", 
      "infiltration", 
      "treatment", 
      "cells", 
      "major advances", 
      "inhibitors", 
      "ipilimumab", 
      "immunotherapy", 
      "patients", 
      "cytokines", 
      "PD1", 
      "microenvironment", 
      "majority", 
      "agents", 
      "study", 
      "benefits", 
      "conditioning", 
      "resistance", 
      "advances", 
      "function", 
      "reasons", 
      "focus", 
      "production", 
      "introduction", 
      "approach", 
      "properties"
    ], 
    "name": "Overcoming Resistance of Melanoma to Immunotherapy with Monoclonal Antibodies Against Checkpoints Inhibitors", 
    "pagination": "143-155", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1009856817"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-1-4614-7654-2_7"
        ]
      }
    ], 
    "publisher": {
      "name": "Springer Nature", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-1-4614-7654-2_7", 
      "https://app.dimensions.ai/details/publication/pub.1009856817"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2022-09-02T16:13", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/chapter/chapter_306.jsonl", 
    "type": "Chapter", 
    "url": "https://doi.org/10.1007/978-1-4614-7654-2_7"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/978-1-4614-7654-2_7'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/978-1-4614-7654-2_7'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/978-1-4614-7654-2_7'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/978-1-4614-7654-2_7'


 

This table displays all metadata directly associated to this object as RDF triples.

117 TRIPLES      22 PREDICATES      65 URIs      57 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/978-1-4614-7654-2_7 schema:about anzsrc-for:11
2 anzsrc-for:1107
3 anzsrc-for:1112
4 schema:author Na7eade82c87f4fa0ad98024d7fbafb7c
5 schema:datePublished 2013-08-04
6 schema:datePublishedReg 2013-08-04
7 schema:description The introduction of monoclonal antibodies against checkpoint inhibitors on T cells such as Ipilimumab and anti PD1 has been a major advance in the treatment of metastatic melanoma. Nevertheless, the majority of patients does not receive benefit from this treatment approach. The reasons for this are likely to reflect conditioning of the microenvironment of the tumour by properties of the tumour cells that either prevent infiltration by T cells or which modulate their function. Treatments that combine monoclonal antibodies with agents that inhibit melanoma cell production of suppressive cytokines and which favor infiltration of T cells into the tumour are the focus of ongoing studies.
8 schema:editor N40da5ebfc2454baea76b48c7a838983a
9 schema:genre chapter
10 schema:isAccessibleForFree false
11 schema:isPartOf N410b44ab6d8649d0b0e8cbcdf71c3e4c
12 schema:keywords Anti-PD1
13 PD1
14 T cells
15 advances
16 agents
17 antibodies
18 approach
19 benefits
20 cell production
21 cells
22 checkpoint inhibitors
23 conditioning
24 cytokines
25 focus
26 function
27 immunotherapy
28 infiltration
29 inhibitors
30 introduction
31 ipilimumab
32 major advances
33 majority
34 majority of patients
35 melanoma
36 metastatic melanoma
37 microenvironment
38 monoclonal antibodies
39 ongoing studies
40 overcoming resistance
41 patients
42 production
43 properties
44 reasons
45 resistance
46 study
47 suppressive cytokines
48 treatment
49 treatment approaches
50 tumor cells
51 tumors
52 schema:name Overcoming Resistance of Melanoma to Immunotherapy with Monoclonal Antibodies Against Checkpoints Inhibitors
53 schema:pagination 143-155
54 schema:productId N9519f0220cce45d0842b4f59fb2c0d73
55 Nfaf09b15966b4c3293508fb4be9f237b
56 schema:publisher Ne924ef8591304db0b5844e967733347d
57 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009856817
58 https://doi.org/10.1007/978-1-4614-7654-2_7
59 schema:sdDatePublished 2022-09-02T16:13
60 schema:sdLicense https://scigraph.springernature.com/explorer/license/
61 schema:sdPublisher Nff552036ac58425f9aed484bb73e2c5c
62 schema:url https://doi.org/10.1007/978-1-4614-7654-2_7
63 sgo:license sg:explorer/license/
64 sgo:sdDataset chapters
65 rdf:type schema:Chapter
66 N1288172f8f8c456fa2dd36ebed76ba92 rdf:first sg:person.01140040522.17
67 rdf:rest rdf:nil
68 N40da5ebfc2454baea76b48c7a838983a rdf:first N4e2178cd37f94b4ea02351c65b6f8657
69 rdf:rest rdf:nil
70 N410b44ab6d8649d0b0e8cbcdf71c3e4c schema:isbn 978-1-4614-7653-5
71 978-1-4614-7654-2
72 schema:name Resistance to Immunotherapeutic Antibodies in Cancer
73 rdf:type schema:Book
74 N4e2178cd37f94b4ea02351c65b6f8657 schema:familyName Bonavida
75 schema:givenName Benjamin
76 rdf:type schema:Person
77 N9519f0220cce45d0842b4f59fb2c0d73 schema:name dimensions_id
78 schema:value pub.1009856817
79 rdf:type schema:PropertyValue
80 Na7eade82c87f4fa0ad98024d7fbafb7c rdf:first sg:person.01073667716.42
81 rdf:rest Nc9cb9fd134ba46a9a7273b833dfe368a
82 Nc9cb9fd134ba46a9a7273b833dfe368a rdf:first sg:person.01167006216.55
83 rdf:rest N1288172f8f8c456fa2dd36ebed76ba92
84 Ne924ef8591304db0b5844e967733347d schema:name Springer Nature
85 rdf:type schema:Organisation
86 Nfaf09b15966b4c3293508fb4be9f237b schema:name doi
87 schema:value 10.1007/978-1-4614-7654-2_7
88 rdf:type schema:PropertyValue
89 Nff552036ac58425f9aed484bb73e2c5c schema:name Springer Nature - SN SciGraph project
90 rdf:type schema:Organization
91 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
92 schema:name Medical and Health Sciences
93 rdf:type schema:DefinedTerm
94 anzsrc-for:1107 schema:inDefinedTermSet anzsrc-for:
95 schema:name Immunology
96 rdf:type schema:DefinedTerm
97 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
98 schema:name Oncology and Carcinogenesis
99 rdf:type schema:DefinedTerm
100 sg:person.01073667716.42 schema:affiliation grid-institutes:grid.412703.3
101 schema:familyName Hersey
102 schema:givenName Peter
103 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01073667716.42
104 rdf:type schema:Person
105 sg:person.01140040522.17 schema:affiliation grid-institutes:grid.412703.3
106 schema:familyName Mijatov
107 schema:givenName Branka
108 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01140040522.17
109 rdf:type schema:Person
110 sg:person.01167006216.55 schema:affiliation grid-institutes:grid.412703.3
111 schema:familyName Gallagher
112 schema:givenName Stuart
113 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01167006216.55
114 rdf:type schema:Person
115 grid-institutes:grid.412703.3 schema:alternateName Kolling Institute of Medical Research, Royal North Shore Hospital, 2065, St Leonards, NSW, Australia
116 schema:name Kolling Institute of Medical Research, Royal North Shore Hospital, 2065, St Leonards, NSW, Australia
117 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...